Home > Products > Antibodies > Biosimilars

Research Grade Bivatuzumab (HB183016)

Price(USD): $

Spec:

100ug
1mg

Number:

Contact us

Overview
Images
References
Datasheet

Overview

Catalog No.	HB183016
Species reactivity	Human
Applications	Research Grade Biosimilar
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Hyaluronate receptor, MDU2, HUTCH-I, MDU3, Phagocytic glycoprotein I, CDw44, Epican, Phagocytic glycoprotein 1, ECMR-III, CD44, Hermes antigen, PGP-1, PGP-I, GP90 lymphocyte homing/adhesion receptor, LHR, CD44 antigen, MIC4, Extracellular matrix receptor III, Heparan sulfate proteoglycan
Concentration	1mg/ml
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G, purified from cell culture supernatant.
Accession	P16070
Form	Liquid
Storage buffer	0.01M PBS,pH7.4.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -110°C.
Alternate Names	BIWA4,CAS:214559-60-1
Background	Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells.
Note	For research use only. Not for use in clinical or therapeutic applications.

Images

References

Datasheet

Research Grade Bivatuzumab.pdf

Recommendation

Research Grade Bivatuzumab